General Information of Drug (ID: DM824EG)

Drug Name
COVA322 Drug Info
Indication
Disease Entry ICD 11 Status REF
Psoriasis vulgaris EA90 Phase 1/2a [1]
Cross-matching ID
TTD Drug ID
DM824EG

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Tumor necrosis factor (TNF)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [3]
Nafamostat DMU1XOD Pancreatitis DC31-DC34 Approved [4]
Pentoxifylline DMU3DNC Alcoholic hepatitis DB94.1 Approved [5]
Lenalidomide DM6Q7U4 Adult T-cell leukemia/lymphoma Approved [6]
Enbrel DM7RNP3 Arthritis FA20 Approved [7]
Golimumab DMHZV7X Psoriatic arthritis FA21 Approved [8]
Certolizumab DM5CL9Z Rheumatoid arthritis FA20 Approved [9]
Etanercept DMCV109 Arthritis FA20 Approved [10]
Adalimumab DMQMV1B Crohn disease DD70 Approved [11]
Infliximab DMH7OIA Crohn disease DD70 Approved [12]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Interleukin-17 (IL17)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brodalumab DMASDQ6 Plaque psoriasis EA90.0 Approved [13]
Bimekizumab DMR9TF1 Plaque psoriasis EA90.0 Approved [14]
Ixekizumab DMXW92T Plaque psoriasis EA90.0 Approved [15]
CNTO-6785 DM6RQXB Rheumatoid arthritis FA20 Phase 2 [16]
ABT-122 DM23UQ9 Psoriatic arthritis FA21 Phase 2 [17]
CJM112 DMTSVJM Acne vulgaris ED80 Phase 2 [18]
SHR-1314 DMADNY3 Plaque psoriasis EA90.0 Phase 1/2 [14]
ABBV-257 DMCZI8L Rheumatoid arthritis FA20 Phase 1 [19]
ALX-0761 DMJ8ACF Psoriasis vulgaris EA90 Phase 1 [2]
SCH-900117 DM7A6R5 Rheumatoid arthritis FA20 Phase 1 [20]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-17 (IL17) TTG0MT6 IL17_HUMAN Modulator [2]
Tumor necrosis factor (TNF) TTF8CQI TNFA_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT02243787) Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis
2 Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
3 Efficacy of different thalidomide regimens for patients with multiple myeloma and its relationship with TNF-alpha level. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Dec;16(6):1312-5.
4 Clinical pipeline report, company report or official report of AstraZeneca (2009).
5 Targeted therapies in myelodysplastic syndromes: ASH 2003 review. Semin Hematol. 2004 Apr;41(2 Suppl 4):13-20.
6 Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009 Apr 15;(2):CD007351.
7 Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loose... J Bone Joint Surg Am. 2001 Jul;83(7):1057-61.
8 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
9 Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96.
10 The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72.
11 Adalimumab for psoriasis patients who are non-responders to etanercept: open-label prospective evaluation. J Eur Acad Dermatol Venereol. 2009 Dec;23(12):1394-7.
12 Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Clin Pract Rheumatol. 2008 Jun;4(6):300-9.
13 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal. Br J Dermatol. 2012 Oct;167(4):710-3; discussion 714-5.
16 Targeting the IL-17-T(H)17 pathway. Nat Rev Drug Discov. 2015 Jan;14(1):11-2.
17 DOI: 10.1136/annrheumdis-2015-eular.4042
18 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov. 2012 Oct;11(10):763-76.